Cellumed Co.,Ltd.

A049180

KR7049180003

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
1,662 ^KRW	-4.48%		+2.28%	-22.70%

Mar. 21	Cellumed Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 07	Cellumed Co.,Ltd. announced that it has received KRW 10.000000362 billion in funding	CI

Cellumed Co., Ltd. announced that it has received KRW 5 billion in funding from Rocket International Co., Ltd, Inscobee., Inc., and other investors

December 02, 2020

On December 3, 2020, Cellumed Co., Ltd. (KOSDAQ:A049180) closed the transaction. The company issued 2,000,000 shares for gross proceeds of KRW 5,000,000,000 in the transaction.

Latest news about Cellumed Co.,Ltd.

Cellumed Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Cellumed Co.,Ltd. announced that it has received KRW 10.000000362 billion in funding	Mar. 06	CI
Cellumed Co.,Ltd. announced that it expects to receive KRW 10.000000362 billion in funding	Feb. 28	CI
Cellumed Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Cellumed Co., Ltd. announced that it has received KRW 3 billion in funding	23-10-05	CI
Cellumed Co., Ltd. announced that it has received KRW 2 billion in funding	23-08-31	CI
Cellumed Co., Ltd. announced that it expects to receive KRW 2 billion in funding	23-08-30	CI
Cellumed Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Cellumed Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Cellumed Co., Ltd. announced that it has received KRW 5 billion in funding from Sangsangin Savings Bank, Investment Arm, Sangsangin Plus Savings Bank, Investment Arm	23-04-04	CI
Cellumed Co., Ltd. announced that it expects to receive KRW 5 billion in funding from Sangsangin Savings Bank, Investment Arm, Sangsangin Plus Savings Bank, Investment Arm	23-03-28	CI
Cellumed Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-22	CI
Cellumed Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-13	CI
Cellumed Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
Cellumed Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Cellumed Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-21	CI
Cellumed Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-14	CI
Cellumed Co., Ltd.(KOSDAQ:A049180) added to S&P Global BMI Index	21-09-20	CI
BH Cell Co., Ltd. announced that it has received KRW 7.5 billion in funding from Cellumed Co., Ltd. and other investors	21-08-30	CI
Cellumed Co., Ltd. announced that it has received KRW 15 billion in funding from High Value Life Science No. 1 Investment Association, BNS Investment Ltd	21-06-01	CI
Cellumed Co., Ltd. announced that it expects to receive KRW 15 billion in funding from High Value Life Science No. 1 Investment Association, BNS Investment Ltd	21-05-13	CI
Cellumed Co., Ltd. acquired an additional 46.3% stake in Hwankyung ENG Co., Ltd. from Free Telecom Co., Ltd. for KRW 10 billion.	21-02-08	CI
Cellumed Co., Ltd. announced that it has received KRW 13.91999 billion in funding from Free Telecom Co., Ltd. and other investors	21-02-07	CI
Cellumed Co., Ltd. announced that it expects to receive KRW 24.2199888 billion in funding from Free Telecom Co., Ltd. and other investors	21-01-28	CI
Cellumed Co., Ltd. cancelled the acquisition of 97.3% stake in Hwankyung ENG Co., Ltd. for KRW 18 billion.	20-12-15	CI

CELLUMED CO., LTD., formerly Korea Bone Bank CO., LTD, is a Korea-based company engaged in the manufacture and sale of medical equipment and biosimilars. The Companyâs products consist of allografts for tissue repair; bone sponges, bone powders and demineralized bone matrixes (DBMs) for bone regeneration; biosimilars, such as bone morphogenetic protein 2 (BMP2) reagents and others, as well as medical devices, such as spinal fixation systems, joint replacements and navigation systems. The Company sells its products within domestic market and to overseas markets.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Medical Devices & Implants

	1st Jan change	Capi.
CELLUMED CO.,LTD.	-22.70%	58.15M
STRYKER CORPORATION	+12.07%	128B
SMITH & NEPHEW PLC	-9.04%	10.65B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+0.91%	8.82B
INSPIRE MEDICAL SYSTEMS, INC.	+16.72%	7.19B
GLAUKOS CORPORATION	+25.15%	4.99B
AXONICS, INC.	+7.17%	3.4B
ENOVIS CORPORATION	-1.36%	3.03B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-8.73%	2.14B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-10.15%	2B